Axcan’s Pylera Clears FDA; Third Name’s The Charm
This article was originally published in The Pink Sheet Daily
Oft-delayed H. pylori treatment will enter $160 mil. U.S. market in 2007.
You may also be interested in...
The firm said it could launch the H. pylori bacteria agent in the first half of 2007.
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.
The results show that cardiac resynchronization defibrillators "slow the progression of heart failure in asymptomatic and mildly symptomatic patients," potentially expanding the market by $600 million.